Kymera Therapeutics (KYMR) Misses Q3 EPS by 26c

Kymera Therapeutics (NASDAQ: KYMR) reported Q3 EPS of ($0.90), $0.26 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $4.73 million versus the consensus estimate of $15.97 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits